Aranesp darbepoetin alfa: Phase II; marketed for anemia associated with chronic renal failure and chemotherapy-induced anemia

Preliminary results from the first 30 of 97 patients in a U.S. Phase II trial showed that all patients met the primary endpoint of maintaining hemoglobin levels in the 10-12 g/dL range while receiving...